| 发明名称 | Pyrimidinyl-diazospiro compounds | ||
| 摘要 | The invention relates to spiro derivatives, to the use of said derivatives intreating diseases and conditions mediated by modulation of voltage-gated sodium channels, to compositions containing said derivatives and processes for their preparation. | ||
| 申请公布号 | US9376445(B2) | 申请公布日期 | 2016.06.28 |
| 申请号 | US201314403473 | 申请日期 | 2013.05.22 |
| 申请人 | Convergence Pharmaceuticals Limited | 发明人 | Giblin Gerard M. P.;MacPherson David T.;Witty David R.;Stanway Steven J. |
| 分类号 | C07D471/10;C07D487/10;A61K31/407;A61K31/438 | 主分类号 | C07D471/10 |
| 代理机构 | Honigman Miller Schwartz and Cohn LLP | 代理人 | Honigman Miller Schwartz and Cohn LLP ;Doyle Kathryn D.;O'Brien Jonathan P. |
| 主权项 | 1. A compound of formula (I) which is 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)-phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one: or a pharmaceutically acceptable salt or solvate thereof. | ||
| 地址 | London GB | ||